On Jun. 29, 2020, Luminex announced that the company had submitted an Emergency Use Authorization request to the FDA for its xMAP SARS-CoV-2 Multi-Antigen IgG assay. The assay was developed to provide additional capacity to detect antibodies in patients who may have been exposed to or infected by SARS-CoV-2.

It delivers excellent results for up to 96 samples in under three hours and is designed to be run on all xMAP platforms, with more than 17,000 systems sold globally, and 65+ Luminex global partners offering 1,300+ kits and custom assay solutions.